Helen Sabzevari Sells 52,870 Shares of Precigen, Inc. (NASDAQ:PGEN) Stock

Posted by Defense World Staff on Aug 6th, 2023

Precigen, Inc. (NASDAQ:PGEN – Get Free Report) CEO Helen Sabzevari sold 52,870 shares of the firm’s stock in a transaction dated Friday, August 4th. The shares were sold at an average price of $1.10, for a total transaction of $58,157.00. Following the completion of the sale, the chief executive officer now owns 1,309,503 shares of the company’s stock, valued at approximately $1,440,453.30. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Precigen Stock Down 0.9 %

Shares of NASDAQ PGEN opened at $1.11 on Friday. Precigen, Inc. has a 1 year low of $0.81 and a 1 year high of $2.90. The firm’s 50-day moving average is $1.22 and its 200-day moving average is $1.14.

Precigen (NASDAQ:PGEN – Get Free Report) last issued its earnings results on Wednesday, May 10th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.02). The business had revenue of $1.85 million during the quarter, compared to the consensus estimate of $3.60 million. Precigen had a net margin of 106.83% and a negative return on equity of 61.83%. As a group, analysts predict that Precigen, Inc. will post -0.42 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of PGEN. Ieq Capital LLC bought a new position in Precigen during the 4th quarter worth approximately $25,000. Cresset Asset Management LLC bought a new position in Precigen during the 1st quarter worth approximately $25,000. Two Sigma Securities LLC bought a new position in Precigen during the 1st quarter worth approximately $25,000. O Shaughnessy Asset Management LLC bought a new position in Precigen during the 4th quarter worth approximately $27,000. Finally, Public Employees Retirement System of Ohio bought a new position in Precigen during the 1st quarter worth approximately $28,000. Institutional investors own 61.77% of the company’s stock.

Wall Street Analyst Weigh In

Separately, JPMorgan Chase & Co. started coverage on shares of Precigen in a research report on Tuesday, May 23rd. They issued a “neutral” rating for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Precigen currently has an average rating of “Hold” and a consensus target price of $10.00.

About Precigen

(Get Free Report)

Precigen, Inc is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases.